MSK Research Highlights for November 16, 2026

Memorial Sloan Kettering Cancer Center

New research from Memorial Sloan Kettering Cancer Center (MSK) shows how BRCA2-mutant cancers rely on a previously unknown DNA repair lifeline; helps explain the effectiveness of cyclophosphamide, a drug used in bone marrow transplants; and finds small cell transformation persists despite early chemotherapy in high-risk EGFR-mutant lung cancer.

BRCA2-mutant cancers rely on a previously unknown DNA repair lifeline

A protein complex that helps fix gaps in damaged DNA turns out to provide a critical lifeline for BRCA2-deficient cancer cells — making it a potential therapeutic target, a new MSK study shows. Mutations in both the BRCA2 and BRCA1 genes are among the most well-known genetic risk factors for breast and ovarian cancers.

The research team — overseen by senior author Simon Powell, MD, PhD , Chair of MSK's Department of Radiation Oncology — investigated how cancer cells lacking BRCA2 manage to survive despite DNA damage caused by the loss of BRCA2. The study was led by postdoctoral researcher Helen Grimsley, PhD .

BRCA2 is a key player in homologous recombination — a critical process cells use to repair broken DNA and ensure accurate genome duplication. When BRCA2 is lost, cells accumulate small gaps in their DNA. Left unfixed, these gaps can grow into serious DNA breaks and ultimately cause the cell to die.

Yet cancer cells with mutations that disable BRCA2 manage to survive. This suggests some unknown repair mechanism keeps these DNA gaps in check — and that's exactly what the Powell Lab identified.

By comparing cancer cells with and without BRCA2, the scientists identified a protein complex called 9-1-1 — made up of RAD9A, RAD1, and HUS1 — that is essential to the survival of BRCA2-deficient cells.

The team found that when BRCA2-deficient cells lose the 9-1-1 complex, the DNA gaps spiral out of control — leading to cell death. That's because 9-1-1 normally prevents an enzyme called EXO1 from expanding the DNA gaps until they're too large to repair.

The scientists confirmed EXO1's critical role in destabilizing cancer cells by removing it — showing cells that lacked both the enzyme and the 9-1-1 complex were able to survive the DNA damage caused by the loss of BRCA2.

The 9-1-1 complex, however, doesn't just act as a brake on EXO1, the researchers found. It also actively recruits a specialized DNA repair polymerase called POL-zeta to fix the DNA gaps. When the researchers blocked the site where POL-zeta interacts with the 9-1-1 complex, the cancer cells lost their ability to repair the gaps.

Importantly, this reliance on the 9-1-1 complex is specific to BRCA2-deficient cells — those lacking BRCA1 did not show the same vulnerability.

The team's laboratory findings were further supported by an analysis of The Cancer Genome Atlas , which found that disease-causing mutations in the BRCA2 gene and in the components of the 9-1-1 complex appear to be mutually exclusive.

"Our findings suggest that targeting the 9-1-1 complex could cause tumors with BRCA2 mutations to self-destruct by taking away this critical DNA repair mechanism that allows them to survive," Dr. Powell says. "And this would target an entirely different DNA repair mechanism than PARP inhibitors, the current standard of care, which cancer cells can become resistant to."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.